Conversely, ADORA2A agonists are considered to be potential treatments for asthma and COPD, since ADORA2A is important for controlling the balance between the immune cells in allergic asthma by simultaneously increasing immunosuppressive Treg cells and decreasing pro-inflammatory Th17 cells in mice (37). This evidence concerns the gene ADORA2A and asthma.